Agenus Inc. (Nasdaq: AGEN) published updated results from its Phase 2 NEST trial evaluating a combination of botensilimab (BOT) and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE